Urticaria Management Guidelines

Initial Assessment and Classification

The American Academy of Allergy, Asthma, and Immunology recommends distinguishing between acute urticaria (≤6 weeks) and chronic urticaria (>6 weeks), as management approaches differ, and evaluating for urticarial vasculitis if wheals last longer than 24 hours (requires skin biopsy) 1

The British Society for Allergy and Clinical Immunology recommends beginning with second-generation (non-sedating) H1-antihistamines such as cetirizine, desloratadine, fexofenadine, levocetirizine, or loratadine, and using standard doses initially for 2-4 weeks to assess response 2, 3
For inadequate response, the American College of Allergy, Asthma, and Immunology recommends increasing antihistamine dose up to four times the standard dose 1

The British Society for Allergy and Clinical Immunology recommends adding H2-antihistamines (such as ranitidine or famotidine) for resistant cases, and considering adding leukotriene receptor antagonists (montelukast) as adjunctive therapy, particularly for aspirin-sensitive and autoimmune urticaria 2, 3, 4
Short courses of oral corticosteroids may be used for acute urticaria (e.g., prednisolone 50 mg daily for 3 days in adults), but should be avoided long-term in chronic urticaria except in very selected cases under specialist supervision 3, 4

In pediatric patients, the American Academy of Pediatrics recommends second-generation H1-antihistamines as the cornerstone of management, with dose and age restrictions varying for younger children 2, 4
In pregnancy, the British Society for Allergy and Clinical Immunology recommends avoiding all antihistamines if possible, especially during the first trimester, but notes that chlorphenamine has the longest safety record in the UK, and loratadine and cetirizine are FDA Pregnancy Category B drugs 3, 4
In renal impairment, the National Kidney Foundation recommends avoiding acrivastine in moderate renal impairment, halving the dose of cetirizine, levocetirizine, and hydroxyzine, and avoiding cetirizine, levocetirizine, and alimemazine in severe renal impairment 4
In hepatic impairment, the American Association for the Study of Liver Diseases recommends avoiding mizolastine in significant hepatic impairment, alimemazine in hepatic impairment, and chlorphenamine and hydroxyzine in severe liver disease due to inappropriate sedating effects 3, 4

The American Academy of Allergy, Asthma, and Immunology recommends minimizing non-specific aggravating factors such as overheating, stress, and alcohol, avoiding drugs that can worsen urticaria, and applying cooling antipruritic lotions (calamine or 1% menthol in aqueous cream) for symptomatic relief 1, 2

For severe antihistamine-resistant chronic urticaria, the American College of Allergy, Asthma, and Immunology recommends considering omalizumab 300mg every 4 weeks, and cyclosporine has been effective in about two-thirds of patients with severe autoimmune urticaria at 4 mg/kg daily 1, 5, 6

The American Academy of Allergy, Asthma, and Immunology recommends regularly assessing disease activity, impact on quality of life, and treatment response, monitoring blood pressure and renal function every 6 weeks for patients on cyclosporine, and considering stepping down therapy after achieving complete control for at least 3 consecutive months 1